Back to Top

Information For Authors

Journal of Adolescent and Young Adult Oncology (JAYAO) welcomes quantitative and qualitative clinical, basic science, and psychosocial manuscript submissions on all topics related to adolescent and young adult-aged cancer patients and survivors, including AYA-aged survivors of pediatric cancer.

JAYAO generally uses the National Cancer Institute's designated AYA age range of 15-39; however, it is acceptable for manuscripts submitted from institutions or countries typically using a younger lower age limit to use the lower age limit as appropriate. For a discussion about the age range included in adolescent and young adult oncology, please see the Controversies piece in JAYAO's inaugural issue (J Adolesc Young Adult Oncol. 2011;1(1):3-10).

All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

Please read all Instructions for Authors carefully before submitting your paper.  All papers are subject to peer review and must be uploaded to the following peer-review website:  https://mc.manuscriptcentral.com/JAYAO

Use of English Language

All submissions must be in English. Appropriate use of English is a requirement for review and publication in Journal of Adolescent and Young Adult Oncology. To support non-native speakers, Mary Ann Liebert, Inc., has partnered with Editage to provide language editing and translation services for a fee prior to official submission. To learn more about the services, please visit the Liebert Author Services website. Please note that employing the use of such services is not mandatory and using it, or any other language editing service, does not guarantee the acceptance of any paper. All submissions are subject to peer review.

Article Types

Note: All articles are peer-reviewed unless otherwise noted. Note the listed limits for text, figures/tables, and references below, but please be concise across all manuscript components. Those interested in an exception to a posted limit must contact the Editors prior to submission.

Original Articles present original quantitative or qualitative basic science, clinical, or psychosocial research

  • Abstract: Standard abstract 250 word limit. See standard abstract guidelines under Manuscript Components.
  • Text: 3,000 word limit.
  • Figures and Tables: Maximum of 8 total figures and/or tables.
  • References: Maximum of 100 references.

Review articles are systematic and critical reviews of the current literature on a topic

  • Abstract: Standard abstract 250 word limit, but structured headings not required.
  • Text: 4,500 word limit. Details on the study selection and inclusion process and on the participants in each selected study should be included.
  • Figures and Tables: Maximum of 10 total figures and/or tables.
  • References: Maximum of 250 references.

Case Study articles are unusual, illustrative, or instructive AYAO-relevant clinical cases

  • Abstract: Include a brief abstract of 100 words or less; structured headings are not required.
  • Text: 1,750 word limit. Include a concise literature review, brief overview of the case, and a brief summarizing conclusion. Be sure to discuss the relevance or importance of the case to AYAO.
  • Figures and Tables: Maximum of 3 total figures and/or tables.
  • References: Maximum of 25 references.

Brief Reports articles are short pieces about pilot studies, preliminary findings, very small sample sizes, or other research findings that are not suitable for a full Original Article

  • Abstract: Include a brief abstract of 100 words or less; structured headings are not required.
  • Text: 2,000 word limit. Include a concise literature review and a brief overview of the study, sufficient details on the study's methods and analysis, and a brief summarizing conclusion.
  • Figures and Tables: Maximum of 3 total figures and/or tables.
  • References: Maximum of 25 references.

Perspective articles are short pieces in which authors share or argue a viewpoint grounded in the literature but not linked to a specific article

  • Abstract: The final print version of accepted Perspective articles will not have an abstract. However, please include a maximum 100 word abstract with the submission to facilitate the review process.
  • Text: 1,500 word limit. The first paragraph should be a brief overview as there is no abstract. The perspective and points should be grounded in the literature. Include a brief summarizing conclusion.
  • Figures and Tables: Maximum of 3 total figures and/or tables.
  • References: Maximum of 25 references.

Letters to the Editor comment on recently published JAYAO articles

  • Special Notes: Letters to the Editor should be submitted within 6 weeks of the article's publication in print form. Include a short title related to but distinct from the recently published article. Provide the standard Title page, but no Running Head or Keywords. The Editors may choose to invite the authors to submit a response to the Letter. Not peer reviewed.
  • Abstract: The final print version of accepted Letters to the Editor will not have an abstract. However, please include a maximum 100 word abstract with the submission to facilitate processing.
  • Text: 500 word limit.
  • Figures and Tables: Maximum of 1 total figure and/or table.
  • References: No more than 5 references, one of which must be the JAYAO article being discussed.


Article Types that are Invite-Only or Require Pre-Submission Inquiry

Roundtable articles are transcribed discussions on a topic by leading members of the AYAO community

  • Invitation only, although those with a suggested topic are welcome to contact the Editors. Not peer reviewed.

Controversies articles include short responses by invited participants to hot topics in AYAO

  • Invitation only, although those with a suggested topic are welcome to contact the Editors. Not peer reviewed.

Clinical Trial Spotlight articles are brief summaries of clinical trials of importance or relevance to AYAO and still open to accrual

  • Invitation only, although those with a suggested topic are welcome to contact the Editors. Not peer reviewed.

Editorial pieces provide commentary and analysis of an article in the issue of JAYAO in which it appears

  • Invitation only. Not peer reviewed.

Book Reviews are 500-750 word pieces critically reviewing a book of AYAO-relevance

  • Invitation only, although those with a suggestion of a book to be reviewed are welcome to contact the Editors. Not peer reviewed.

Special Articles may include guidelines, meeting summaries, consensus statements, or other non-standard communications

  • Please contact the Editors prior to submission. May be subject to peer review.


Online Manuscript Submission

Manuscripts must be uploaded to Manuscript Central in a word processing format, preferably in Microsoft Word. Do not submit the manuscript or any of its components in PDF format. All authors on a submitted manuscript must have a Manuscript Central account.

Keywords and Abstract

Please note the keywords and abstract entered online in Manuscript Central are only to aid with the review process and are separate from the keywords and abstract on the title page for inclusion in the article.

Suggested Reviewers

Authors are encouraged to suggest the names and emails of appropriate reviewers, at least one of whom is not a member of JAYAO’s Editorial Board, during Manuscript Central submission, though final selection of reviewers is at the discretion of the Editors.

Cover Letter

Please include a cover letter from the corresponding author. The cover letter should include the following:

  • Running head character count (including spaces)
  • Abstract word count
  • Main text word count
  • Number of tables
  • Number of figures
  • Number of appendices (if applicable)
  • If the authors have published or submitted any related papers from the same study
  • If pre-submission permission was obtained to exceed the article type’s word limit
  • Authors are encouraged to detail the significance and uniqueness of the work

PUBLICATION ETHICS AND MALPRACTICE STATEMENT

 

Study Design and Ethics

Documented review and approval from a formally constituted review board (Institutional Review Board or Ethics committee) should be required for all studies involving people, medical records, and human tissues. For those investigators who do not have access to formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. If the study is judged exempt from review, a statement from the committee should be required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and a sentence declaring adherence should be included in the acknowledgment section of the manuscript.
 

Animal experiments should require full compliance with local, national, ethical, and regulatory principles, and local licensing arrangements.
 

Definitions of Scientific Misconduct
 

Mary Ann Liebert, Inc., publishers generally follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).

Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:

  • Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
     
  •  Authorship Disputes: Deliberate misrepresentation of a scientist’s contribution to the published work, or purposefully omitting the contributions of a scientist.
     

  • Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.
     

  • Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.
     

  • Material failure to comply with legislative and regulatory requirements affecting research:
    Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.
     

  • Conflict of Interest:  Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
     
  • Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
     
  • Plagiarism: Purposely claiming another’s work or idea as your own constitutes misconduct and/or fraud.
     

  • Simultaneous Submission:  Submitting a paper to more than one publication at the same time constitutes misconduct.

Responding to Allegations of Possible Misconduct
 

The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation.  As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.
 

When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper.  In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.
 

Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.
 

If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record.  If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.
 

All allegations will be kept confidential.

Manuscript Components

General Formatting and Style

  • Use of English Language: All submissions must be in English. JAYAO uses American-style English
  • Plagiarism: All submitted manuscripts will be processed through plagiarism detection software. Plagiarized manuscripts will be rejected
  • Word limits: See word limits under Article Types. Word limits do not include the Title Page, headings, Abstract, Acknowledgments, Disclaimer, Author Disclosure Statement, References, Figures, Tables, or legends. Permission to exceed an article type’s word limit must be given by the Editors prior to submission
  • Font: Times New Roman or Arial in 12-point type
  • Abbreviations: Expand all abbreviations at first mention in the text
  • Page size: Letter size (8.5 x 11 inches)
  • Margins: 1 inch
  • Line and word spacing: Double-space all lines; single-space all words
  • Page numbering: Number all pages in the lower-right corner. Do not include anything else in the header or footer

Title Page

The title (first) page of all manuscripts must contain the following information:

Exact title:

  • No proprietary names, trade names, or abbreviations

For each author:

  • Full name, including middle initial if applicable
  • Primary academic degrees (such as MD, DO, PhD, MPH, etc. No undergraduate or honorary degrees, fellowship or society memberships, etc.)
  • Institutional affiliation(s)
  • City, state, and country for each affiliation
  • Email address
  • Note:
    • - Group authors (i.e., “…on behalf of the XYZ Study”) are permissible
    • - Co-first authors are also permitted. On the title page, please put an asterisk after each co-first author and note them as such

Corresponding author:

  • Full name, including middle initial if applicable
  • Primary academic degrees (such as MD, DO, PhD, MPH, etc. No undergraduate or honorary degrees, fellowship or society memberships, etc.)
  • Institutional affiliation(s)
  • City, state, and country for each affiliation
  • Full mailing address
  • Phone number
  • Fax number
  • Email address

Running head:

  • 60 characters or fewer (including spaces, abbreviations acceptable)

Keywords:

  • Provide 4-6 keywords to be included in the article
  • Please do not use cancer, oncology, AYA, or adolescent and young adult as these are inherent in the journal itself

Abstract

A structured abstract using the following guidelines should accompany every manuscript unless otherwise noted above under Article Types. The abstract should appear on a separate page after the title page. The abstract should be no more than 250 words, formatted with the following headings:
              - Purpose
              - Methods
              - Results
              - Conclusion

  • Do not use proprietary or trade names
  • References are not permitted in the abstract
  • Headings do not contribute toward abstract word count

Acknowledgments

After the Conclusion of the main body of the manuscript, include a separate section acknowledging any contributors who did not meet the requirements for authorship and any science writers or corporate employees who participated in the development of the manuscript. Also include acknowledgments of research support for the study.

Disclaimer

After the Acknowledgments section, include a “Disclaimer” section, if needed, for the following:

  • Detail any important disclaimers (for example, the primary data collection organization for a secondary-analysis article)
  • Provide all appropriate details if any part of the manuscript was previously presented

Author Disclosure Statement

Following the Acknowledgments section (or Disclaimer if one was included), include a section entitled ‘‘Author Disclosure Statement.’’ Here authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals for further guidance. If no conflicts exist, the authors must state ‘‘No competing financial interests exist.’’

References

Authors are responsible for the accuracy and completeness of their references. Number references in the order they are cited in the text; do not alphabetize. In-text citations should be in numerical order, superscripted, not contained within parentheses or brackets, and placed after punctuation.

Reference section:

  • Check the Article Types section for reference number limits for some article types
  • Begin the Reference section on a separate page after the Author Disclosure Statement section
  • Double-space all lines and single-space between words
  • Articles accepted and in press are included in the Reference section
  • Personal communications, unpublished data, or manuscripts “in preparation” or “submitted for publication” should not be included in the Reference section. If necessary, these should be included at the appropriate place in the body of the text. Personal communications should include the contact’s first initial and last name, and the month and year of the communication
  • List all authors and/or editors up to 4; for 5 or more, list the first 3 followed by “et al.”
  • For books, volume and edition numbers should be included when appropriate
  • Abbreviate journal names in accordance with PubMed / MEDLINE   
  • No PMIDs or PCMIDs
  • References that are abstracts should be indicated as such, with the abstract number included, if applicable
  • Citation formats are based on NLM style, please see below for specific JAYAO format examples

Examples:

Journal article with 1-4 authors:

1.   Evan EE, Kaufman M, Cook AB, Zeltzer LK. Sexual health and self-esteem in adolescents and young adults with cancer. Cancer. 2006;107(7 Suppl):1672-9.

Journal article with 5 or more authors:

2.   Absolom K, Eiser C, Michel G, et al. Follow-up care for cancer survivors: views of the younger adult. Br J Cancer. 2009;101(4):561-7.

Abstract:

3.   Mullighan CG, Miller CB, Phillips LA, et al. IKZF1 (Ikaros) deletions are a hallmark of BCR-ABL1 positive acute lymphoblastic leukemia. Blood. 2007;110:abstract 721.

Book:

4.   Quinn GP, Vadaparampil ST (Eds). Reproductive health and cancer in adolescents and young adults. New York: Springer; 2012.

Chapter in a Book:

5.   Eiser C, Kuperberg A. Psychological support for adolescents and young adults. In: Bleyer WA, Barr RD (Eds). Cancer in adolescents and young adults. New York: Springer; 2007; pp. 365-74.

Report:

6.   Adolescent and Young Adult Oncology Progress Review Group. Closing the gap: research and cancer care imperatives for adolescents and young adults with cancer (NIH Publication No. 06-6067). Bethesda, MD: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, and the LIVESTRONG Young Adult Alliance; August 2006. Accessed February 7, 2011 from: https://www.cancer.gov/types/aya/research/ayao-august-2006.pdf

Tables

Within the text, cite tables in the order in which they appear using Arabic numerals. Tables in accepted articles will be typeset and placed near the first mention of the table in the text; do not include separate lines indicating table placement.

Table guidelines:

  • Check the Article Types section for limits on the number of tables and/or figures for some article types
  • Either prepare all tables on separate pages in the main document following the References section OR submit each table as a separate word processing document. Do not embed tables within the main body text
  • Provide a brief but descriptive title for each table. Avoid abbreviations in the table title when possible
  • Table footnote(s) should include any essential notes and must include definitions of all abbreviations and acronyms used in the table

Figures

Within the text, cite figures in the order in which they appear using Arabic numerals. Figures in accepted articles will be typeset and placed near the first mention of the figure in the text; do not include separate lines indicating figure placement.

Figure guidelines:

  • Check the Article Types section for limits on the number of tables and/or figures for some article types
  • Figures include graphs, charts, diagrams, illustrations, and photographic images
  • File types and guidelines:
    - All figures must be submitted as separate picture files. Do not embed figures in the main word processing document
    - Do not submit figures as PDFs, PowerPoint, or Excel files
    - To ensure proper print quality, please submit only TIFF or EPS files. JPEG files are for screen representation-quality only and will print very poorly during the printing process
    - Line illustrations should be submitted at 900 DPI.  Halftones and color should be submitted at a minimum of 300 DPI
  • Color figures:
    - Color art must be saved as CYMK, not RGB. (Note: If RGB files are submitted, the files will be converted to CYMK and some color variation will occur)
  • Figure legends:
    - After the Reference section of the main word processing document (or any Tables included in the word processing document), include a separate page with the following information for each figure:
    - Provide a brief but descriptive title for each figure. Avoid abbreviations in the figure title when possible
    - Define all relevant information in figures, including figure part labels, footnotes, abbreviations, acronyms, arrows, and levels of magnification in insets

 NOTE: If supplied, Supplemental Information will not be copyedited or typeset; it will be posted online as supplied.)

Online-Only Materials

Appendices and other supplementary materials should be included only when they are pertinent to the submitted manuscript but beyond the word or table/figure limits.

Appendix and supplementary material guidelines:

  • Published only with the online version of an accepted article
  • The print version of the article will include a URL directing readers to the online-only materials
  • Should be important to understanding or interpretation of the manuscript and limited in length
  • Should be original and not previously published
  • Acceptance of online-only materials is separate from acceptance of the manuscript and at the Editors’ discretion
  • Authors are encouraged to contact the Editors prior to submission of online-only materials

Helpful Hints

  • Clarification of ‘AYA’: Abstracts and the beginning of manuscripts should clearly distinguish whether ‘AYA-aged patients,’ ‘AYA-aged survivors (of AYA cancer),’or ‘AYA-aged survivors (of pediatric cancer)’ are being discussed
  • Variations of ‘AYA’: Authors should use the terminology most appropriate to their manuscript’s age range and country or institution. While ‘adolescent and young adult (AYA)’ is most commonly used in JAYAO, ‘teenage and young adult (TYA),’ ‘young adult (YA),’ adolescent, and other such variations may be used as appropriate
  • Description of age: All manuscripts must clearly state the age range included in both the abstract and main body. Manuscripts discussing survivors must include information about participants’ age both at diagnosis and at study
  • Background and introduction of AYAO in manuscripts: As JAYAO is an entirely AYA-focused journal, please be mindful that the background or introduction section of a manuscript submitted to JAYAO may not need to be as long nor as detailed as an AYAO-focused manuscript submitted to another journal
  • Pre-submission inquiry for manuscripts exceeding word limits: Permission to exceed an article type’s word limit must be given by the Editors prior to submission
  • Revision word limits: Article type word limits apply to revisions as well as initial submissions
  • Pre-submission inquiry for manuscripts with online-only appendices: Authors are encouraged to contact the Editors prior to submission of online-only materials
  • Duplicate author/reviewer accounts in Manuscript Central: Please do not create a duplicate author account when entering authors for a newly-submitted manuscript. If details of an account need to be altered, please contact the Editors
  • Questions and inquiries: Please direct all questions and inquiries to the Editors

 

Permissions

Authors are responsible for procuring permissions to reproduce illustrations or tables taken from other publications and must be acknowledged by a complete credit line in the figure legend. The original publisher’s letter of permission should be available for submission to Journal of Adolescent and Young Adult Oncology if requested by the Editors or the Publisher. A full citation should also be included in the Reference section.

POST-SUBMISSION INFORMATION

Submission-Related Emails and Online Status

The Manuscript Central system sends emails only to the corresponding author (except for copyright release emails for accepted articles). Submitted manuscripts will show in the Manuscript Central Author Center of only the corresponding author.

Manuscript Decisions

Manuscripts may receive decisions of Reject, Major Revision, Minor Revision, Accept with Edits, or Accept. A manuscript decision of Major Revision or Minor Revision does not guarantee the manuscript will ultimately be accepted. Article type word limits apply to revisions as well as initial submissions. A manuscript with a decision of Accept with Edits will not receive a formal Accept decision until all requested edits are satisfactorily completed.

POST-ACCEPTANCE INFORMATION

 Open Access publishing option -- Contact:  OpenAccess@liebertpub.com

 

Page Proofs

An email containing a link to the PDF file of the page proof is sent to the corresponding author. The proof should be read carefully and returned within 3 business days to the Publisher with the author’s/authors’ approval or corrections.

Reprints

Reprints may be ordered by following the special instructions that accompany page proofs and should be ordered at the time the corresponding author returns the corrected page proofs. Reprints ordered after an issue is printed will be charged at a substantially higher rate.

Publisher

Journal of Adolescent and Young Adult Oncology is published bimonthly (six times a year) by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215, Tel: (914) 740-2100; Fax: (914) 740-2101; Email: info@liebertpub.com;  Website: www.liebertpub.com/JAYAO

Publisher Policies

All Mary Ann Liebert, Inc. journals follow the standards, guidelines, and best practices set forth by the -Committee on Publication Ethics (COPE; publicationethics.org), the International Committee of Journal Medical Editors (ICJME; www.icmje.org), the World Medical Association (WMA); www.wma.net) and the American Medical Association (www.ama-assn.org).

Journal of Adolescent and Young Adult Oncology is a single-blinded peer-reviewed journal. All submissions are subject to peer review. Upon submission, manuscripts are assessed by an editor for suitability for the journal.  For those that are deemed suitable, a minimum of two expert reviewers in the area of study will be selected to assess the scientific basis and significance of the manuscript. Following peer review, the Editor and/or Associate Editors will determine if the paper should be accepted, require revision, or is unacceptable for publication.

Confidentiality in Peer Review

Editors and reviewers must maintain strict confidentiality of manuscripts during the peer-review process. Sharing a manuscript in whole or in part, outside the scope of what is necessary for assessment, is impermissible prior to an accepted manuscript's official publication date.

Sharing of Materials during Peer Review

Authors must honor any reasonable request for materials, methods, or data necessary to reproduce or validate the research findings during peer review unless it violates the privacy or confidentiality of human research subjects.

Papers Authored by the Editor-in-Chief and/or Associate Editors

The Editor-in-Chief and Associate Editors will recuse themselves from participating in the review process of any manuscript in which there is a potential or actual competing interest.

Self-Citation and Self-Plagiarism

Journal of Adolescent and Young Adult Oncology is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles. All manuscripts will be processed through plagiarism detection software prior to peer review. Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content (i.e., Materials and Methods) compared to work previously published by authors, self-plagiarism can infringe upon copyright. To avoid plagiarism, be sure to properly cite and reference all published works. (Deposition of a preprint on a preprint server is not considered as prior publication and will not impact consideration of any submitted manuscript.)

Time in Review

Journal of Adolescent and Young Adult Oncology strives to maintain a short, but thorough peer-review process. The average time in review is 32 days but the Editor will strive to expedite manuscript handling if circumstances dictate.

ATTENTION:  To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.
 

AUTHORSHIP

Definition of Authorship

Authorship, as defined by the International Committee of Medical Journal Editors, is based on the following criteria:

  • Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
  • Drafting the work or revising it critically for important intellectual content; AND
  • Final approval of the version to be published; AND
  • Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Non-Author Contributors

Contributors who meet fewer than all four of the above criteria for authorship should not be listed as authors, but they should be acknowledged in the Acknowledgments section with a description of their contribution to the work.

For further information, visit the International Committee of Medical Journal Editors’ website at: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html

ORCID IDs

All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

AUTHORSHIP LIMIT

There is a limit of 35 of authors permitted on a single submission, but in cases where there are 20 or more co-authors, Journal of Adolescent and Young Adult Oncology recommends that a collective group or consortium name be provided and the individual authors listed in the Acknowledgements.

CORRESPONDING AUTHOR**

One author should be designated as the corresponding author who will be responsible for communication between the authors and the journal editorial office(s) and publisher. This individual will be responsible for ensuring all authors submit copyright forms and coordinating and responding to page proofs, as well as any managing any other necessary contact during the peer review and/or production processes.

**NOTE: Due to configuration restraints, the submission system permits only one author to be identified as the corresponding author of record. However, we recognize that some submissions call for more than one corresponding author to be noted. In such cases, select one author to be the main point of contact and/or corresponding author for all communications regarding the peer review process of the paper, but on the title page of the manuscript, designate additional co-corresponding authors by including an asterisk after the authors' names in the byline, and include an accompanying footnote on the title page that reads, "*Co-corresponding authors."  Please ensure that the title page of the submission page carries the full affiliation details and email addresses of all authors who should be noted as a corresponding author. If the paper is accepted for publication, the full contact information for all desginated co-authors will be listed at the end of the article as per usual journal style.

WORKING GROUPS / TEAM AUTHORSHIP

Working Groups or Teams may be listed in the manuscript byline, but the entire listing of names and affiliations should be included in the acknowledgment section of the manuscript. Do not list the names in a footnote on the title page.

VARIATIONS OF AUTHORSHIP

It is permissible to list up to three authors as co-first authors, or as contributing equally to the work. Include an asterisk (*) next to the authors' names who are considered as first authors. Include a corresponding footnote, using the asterisk, on the title page that reads, "These authors contributed equally to this work and are considered to be co-first authors."

CHANGES IN AUTHORSHIP

Changes in authorship after submission or acceptance of a paper are strongly discouraged, but the editorial leadership recognizes that in certain circumstances, it may be required. The journal's policy for such cases is as follows:

  • A request to alter authorship must be made in writing from the corresponding author to the Editor-in-Chief, with a detailed explanation for the request, and the names and affiliations of the authors requiring addition and/or deletion.
  • Authorship may be altered after submission or acceptance of a paper ONLY with the expressed written approval of all authors named on the manuscript, as well as the individual(s) being added and/or deleted. The Publisher can provide a form for this, if needed.
  • Upon receipt of the request and all written approvals of all involved parties, the Editor-in-Chief will consider the request, render a decision, and notify the corresponding author.
  • There is a one-year post-publication statute of limitation on requests for alterations in authorship.
  • Post-publication changes or alterations to conference abstracts are prohibited.

ATTENTION: To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

EXCLUSIVITY

Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, in the same form or substantially similar form, except in the form of a conference abstract.  If work was presented at a conference, supply the name, date, and location of the meeting as a footnote on the title page of the submission.

AUTHOR DISCLOSURE STATEMENTS

  • Competing Interests. A competing interest exists when an individual (or the individual's institution) has financial or personal relationships that may inappropriately influence his actions. These competing interests may be potential or actual, financial or other.
  • Personal Financial Interests. Stocks or shares in a company that may gain or lose financially from publication of the article; consulting fees or other remuneration from an organization that may gain or lose financially from publication of the article; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of the article.
  • Funding. Research support by organizations that may gain or lose financially from publication of the article. This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.
  • Employment. Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of the article.
  • Other Competing Interests. Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgment.

SELF-CITATION AND SELF-PLAGIARISM

Journal of Adolescent and Young Adult Oncology is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles. All manuscripts will be processed through plagiarism detection software prior to peer review. Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content (i.e., Materials and Methods) compared to work previously published by authors, self-plagiarism can infringe upon copyright. To avoid plagiarism, be sure to properly cite and reference all published works.

AFFILIATIONS

Authors should identify as their institution(s) the facility where the work was performed and executed.  Changes in an author’s affiliation after the work was completed but prior to the submission or publication of the manuscript should be noted by including an asterisk as a superscript to the name in the author listing, as well as a corresponding footnote on the title page indicating “Current Address” listing the new affiliation.   Corrections to affiliations or contact information due to relocation after publication is not permitted.

REPRINTS

Reprints may be ordered by following the special instructions that will accompany the proofs and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher as reprints ordered after the issue is printed will be charged at a substantially higher rate.

Word limits do NOT pertain to the abstract, disclosure statements, author contribution statements, funding information, acknowledgments, tables, figure legends, or references.

All articles are peer reviewed unless otherwise noted. Note the listed limits for the abstract, text, figures/tables, and references below, but please be concise across all manuscript components.

Those interested in an exception to a posted limit must contact the Editors prior to submission.


Original Articles
Original Articles present original quantitative or qualitative basic science, clinical, or psychosocial research.
•    3,000-word limit
•    Structured abstract of no more than 250 words, with the following headings: Purpose; Methods; Results; Conclusion.
•    Maximum total of eight (8) figures and/or tables
•    Maximum of 100 references

Review Articles
Review articles are systematic and critical reviews of the current literature on a topic.
•    4,500-word limit
•    Abstract of no more than 250 words (structured headings are not required)
•    Details on the study selection and inclusion process and on the participants in each selected study should be included.
•    Maximum total of ten (10) figures and/or tables
•    Maximum of 250 references

Brief Reports
Brief Reports are short pieces about pilot studies, preliminary findings, very small sample sizes, or other research findings that are not suitable for a full Original Article.
•    2,000-word limit
•    Include a brief abstract of 100 words or less; structured headings are not required.
•    Include a concise literature review and a brief overview of the study, sufficient details on the study's methods and analysis, and a brief summarizing conclusion.
•    Maximum total of three (3) figures and/or tables
•    Maximum of 25 references

Case Studies
Case Study articles are unusual, illustrative, or instructive AYAO-relevant clinical cases.
•    1,750-word limit
•    Include a brief abstract of 100 words or less; structured headings are not required.
•    Include a concise literature review, brief overview of the case, and a brief summarizing conclusion. Be sure to discuss the relevance or importance of the case to AYAO.
•    Maximum total of three (3) figures and/or tables
•    Maximum of 25 references

Perspectives
Perspective articles are short pieces in which authors share or argue a viewpoint grounded in the literature but not linked to a specific article.
•    1,500-word limit
•    The final print version of accepted Perspective articles will not have an abstract. However, please include a maximum 100 word abstract with the submission to facilitate the review process.
•    The first paragraph should be a brief overview as there is no abstract. The perspective and points should be grounded in the literature. Include a brief summarizing conclusion.
•    Maximum total of three (3) figures and/or tables
•    Maximum of 25 references

Letters to the Editor
Letters to the Editor comment on recently published JAYAO articles.
Special Notes: Letters to the Editor should be submitted within 6 weeks of the article's publication in print form. Include a short title that is related to but distinct from the recently published article. Provide the standard title page, but no running head or keywords. The Editors may choose to invite the authors to submit a response to the Letter. Not peer reviewed.
The final print version of accepted Letters to the Editor will not have an abstract. However, please include a maximum 100 word abstract with the submission to facilitate processing.
•    500-word limit
•    May include one figure OR table
•    Reference citations are identical in style to those of full original articles, but should not exceed five (5). One of the references must be the JAYAO article being discussed.

Article Types that are by Invitation Only or Require Pre-Submission Inquiry

Roundtable articles are transcribed discussions on a topic by leading members of the AYAO community.
•    Invitation only, although those with a suggested topic are welcome to contact the Editors. Not peer reviewed.

Controversies articles include short responses by invited participants to hot topics in AYAO.
•    Invitation only, although those with a suggested topic are welcome to contact the Editors. Not peer reviewed.

Clinical Trial Spotlight articles are brief summaries of clinical trials of importance or relevance to AYAO and still open to accrual.
•    Invitation only, although those with a suggested topic are welcome to contact the Editors. Not peer reviewed.

Editorial pieces provide commentary and analysis of an article in the issue of JAYAO in which it appears.
•    Invitation only. Not peer reviewed.
•    1,000-word limit
•    No abstract
•    No figures or tables
•    Maximum of 10 references

Book Reviews are 500-750-word pieces critically reviewing a book of AYAO-relevance.
•    Invitation only, although those with a suggestion of a book to be reviewed are welcome to contact the Editors. Not peer reviewed.
Special Articles may include guidelines, meeting summaries, consensus statements, or other non-standard communications.
•    Please contact the Editors prior to submission. May be subject to peer revie

 

INTERNAL REVIEW BOARD APPROVALS/WAIVERS

(as described and defined on the World Medical Association's website; www.wma.net)

When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Declaration of Helsinki as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.


If the study is judged exempt from review, a statement from the committee is required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and in a sentence declaring adherence should be included in the Materials and Methods section of the manuscript.

ETHICS OF EXPERIMENTATION

All articles involving the use of human fetuses, fetal tissue, embryos, and embryonic cells must adhere to the US Public Law 103–41, effective December 13, 2001. (http://ethics.od.nih.gov/).

ETHICAL TREATMENT OF ANIMALS

All peer-reviewed submissions containing animal experiments must comply with local and national regulatory principles and contain a statement in the Materials and Methods section stating whether their national and institutional guidelines for the care and use of laboratory animals were followed.

For further information, consult the World Medical Association’s website: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

AUTHOR DISCLOSURE STATEMENTS

  • Competing Interests. A competing interest exists when an individual (or the individual's institution) has financial or personal relationships that may inappropriately influence his actions. These competing interests may be potential or actual, financial or other.
  • Personal Financial Interests. Stocks or shares in a company that may gain or lose financially from publication of the article; consulting fees or other remuneration from an organization that may gain or lose financially from publication of the article; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of the article.
  • Funding. Research support by organizations that may gain or lose financially from publication of the article. This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.
  • Employment. Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of the article.
  • Other Competing Interests. Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgment.

INTERNAL REVIEW BOARD APPROVALS/WAIVERS

(as described and defined on the World Medical Association's website; www.wma.net)

When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Declaration of Helsinki as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.

If the study is judged exempt from review, a statement from the committee is required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and in a sentence declaring adherence should be included in the Materials and Methods section of the manuscript.

COPYRIGHT AGREEMENT FORM

Upon acceptance of any manuscript, all authors will receive an email with detailed instructions and a unique, author-specific link to access and complete our online Copyright Agreement form. It is critical to ensure the accuracy of ALL authors' email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications. FAILURE BY ALL AUTHORS TO SUBMIT THIS FORM WILL RESULT IN A DELAY OF PUBLICATION. The corresponding author is responsible for communicating with coauthors to ensure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright. Copyright forms may also be completed by logging in to the system using an author's credentials. After logging on, click on Author Center and complete the forms located under "Manuscripts I Have Coauthored."

Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc., unless alternate arrangements are made prior to publication, including CC-BY licensing (see below). By submitting a manuscript to the Journal, the author(s) agree(s) to each of the above conditions. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal.

OPEN ACCESS / CC-BY LICENSING

Journal of Adolescent and Young Adult Oncology is a subscription-based peer-reviewed journal with Open Access options. Creative Commons CC-BY and CC-BY-NC licensing is available for all articles published open access for a standard Article Processing Charge (APC) of $3,200.00 USD. Please contact our Open Access Manager to order open access for your article. Learn more about open access publishing on our website.

PERMISSIONS

When reproducing copyrighted material such as figures, tables, or excerpted text, the author(s) of the submitted paper must obtain permission from the original publisher and submit it concurrently with the manuscript. The publication from which the figure or table is taken must be listed in the reference list. Finally, a footnote to a reprinted table or the legend of a reprinted figure should read, "Reprinted by permission from Jones et al." and list the appropriate reference. All permissions must be supplied at the time of submission.  Authors are responsible for any fees that may be incurred by securing permission to reproduce or adapt material from other published sources.

REUSE OF MATERIAL POSTED ON SOCIAL MEDIA

As material posted on social media platforms is usually not peer-reviewed content, it is not permitted as an official citation and/or reference.

Mary Ann Liebert, Inc., publishers permits the use of accepted pre-published manuscripts for the sole purpose of pitching to news organizations under strict embargo, and with the approval of and expressed collaboration with the publisher. A watermarked PDF version of the article (not a Word document or any other editable version) may be shared only with named, personal contacts at trusted news sources upon request. News sources must be informed upon delivery of the PDF that the manuscript is for reference-only purposes and can be used only in preparation of their news coverage of the article. It is strictly prohibited to publicly share, post, or otherwise distribute the PDF in any media format. Upon official publication of the article, news organizations must link directly to the published article on the publisher’s journal website. To coordinate publication timing and press efforts, please contact the Director of Marketing, Kathryn Ryan (kryan@liebertpub.com).

DATA SHARING

Journal of Adolescent and Young Adult Oncology strongly advocates the sharing and archiving of the data and any other artifacts that define and support the results stated in a manuscript in a suitable public repository (in accordance with valid privacy, legal, and ethical guidelines). A data availability statement should be included in the manuscript (in the Methods section or as a separate section at the end of the manuscript), describing the location of the data, with details on how it can be accessed as well as any licensing information. If the data is not publicly available or accessible, that information should also be provided.

Datasets should be cited in the reference list by Author (Year). Title. Publisher. Identifier/DOI.

Important: Please check with your funding agencies to ensure that are you following their data sharing polices. If your funding agency has additional requirements exceeding our policy, you must follow the requirements of your funder.

PREPRINT SERVERS

A preprint is a complete draft of a research paper that is shared on a public preprint server prior to submission to a journal for peer review.
 
Mary Ann Liebert, Inc., allows for papers that were previously deposited on preprint servers to be submitted to our journals, with the proviso that the author updates any preprint versions with a link to the final published article.  All submissions are subject to peer review and allowing the submission of preprint manuscripts does not guarantee publication in any Mary Ann Liebert, Inc., journal.
 
The submitting author of a paper that was previously deposited to a preprint server should include a disclosure on the title page of the manuscript indicating the name and website of the server and include the DOI number of the preprint.
 
Referencing/citing non-peer-reviewed material that is found on any preprint server is generally discouraged by Mary Ann Liebert, Inc., journals, but if it is necessary, the citation must make it clear that the content is not officially published in a journal, and can only be found on a preprint server.

 

RESEARCH FUNDER COMPLIANCE (FundRef)

Upon submission of a manuscript, the submitting agent will have an opportunity to enter funding/grant information. If funding information is entered correctly, the publisher will deposit the funding acknowledgements from the article as part of the standard metadata to FundRef. The entered information should include funder names, funder IDs (if available), and associated grant numbers.  Special care should be taken when entering this information to ensure total accuracy. (See https://www.crossref.org/services/funder-registry/ for a listing of more than 13,000 international funding agencies.)

GOVERNMENT FUNDED RESEARCH

Journal of Adolescent and Young Adult Oncology is fully NIH-, HHMI-, RCUK, and Wellcome Trust-compliant.

OPEN ACCESS

Our open access publishing solutions allow you to comply with the open access policies of your institution, government, and funding body. If you are employed or funded by the National Institute of Health (NIH), the Wellcome Trust, Research Councils UK (RCUK), or Howard Hughes Medical Institute (HHMI), you can find more information below:

  • NIH and HHMI Public Access Policy–In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final paginated version of the published article to PubMed Central (PMC) on behalf of the authors after a 12-month embargo period. Authors need not take any action. This service is provided free of charge. Authors who wish to remove the 12-month embargo period are encouraged to consider publishing with Open Option.
  • Wellcome Trust Policy–To easily comply, you can choose to have your article published open access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the Wellcome Trust.
  • Research Councils UK (RCUK)–To easily comply, you can choose to have your article published Open Access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the RCUK.

ATTENTION: To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

POST-ACCEPTANCE / PRODUCTION

All accepted manuscripts will go through copyediting, typesetting, figure sizing and placement, author proofing, corrections, revisions (from corrected proofs), online-ahead-of-print release, and lastly, issue assignment. Depending on the length and complexity of any accepted submission, these steps typically take 3-6 weeks from acceptance.  Changes or alterations to a submission are not permitted after acceptance, but should be addressed in page proofs.

PAGE PROOFS

Page proofs will be sent to the corresponding author as designated in Manuscript Central when the manuscript was submitted. It is the corresponding author's responsibility to share the page proofs with co-authors, if desired, and to coordinate all authors' corrections into one proof. The Publisher will not accept corrections from multiple authors/sources.

AUTHOR RESPONSE TO GALLEY PROOF

  • The corresponding author is responsible for returning corrected galley proofs generally within 72 hours of receipt.
  • If the corresponding author does not respond within that timeframe, the manuscript may be delayed in the publication schedule, or published as is, at the discretion of the Editor and Publisher.
  • If the corresponding author expects to be unavailable during the time the manuscript is in production, the publisher should be provided with an alternate contact. 
  • Only corrections directly related to errors in typesetting and/or layout will be allowed.
  • Any requested changes related to content, or that alter the outcome of a study, will require the approval of the Editor, and may require further peer review.

REPRINTS

Reprints may be ordered by following the special instructions that will accompany the proofs and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher as reprints ordered after the issue is printed will be charged at a substantially higher rate.

POST-PUBLICATION CORRECTIONS

In the event an error is discovered after publication of an article, the corresponding author should submit the correction in writing to the editorial office for consideration.  After editor approval, alterations will be made to the online version of the article, and if the errors are significant, an official correction statement will be issued.

  • Changes to author affiliations or contact details due to relocation after publication are not permitted.
  • Corrections to meeting abstracts will be made only to the online version.  The Journal does not issue formal correction statements for corrections to meeting abstracts, regardless of the nature of the correction.
  • Correction Statements/Errata to published articles that require the reproduction of color figure(s) and/or table(s) may incur additional costs to the author(s).

RETRACTIONS**

The journal and its publisher are committed to upholding the proper protocols and established standards of peer review.  Published papers found to be in violation of any of the misconduct noted above, or in the accepted principles of peer review and scientific publishing, will be officially retracted from the literature.  An official retraction notice explaining in full detail the circumstances surrounding the need for a retraction.

**Any publication fees for retracted and/or withdrawn articles are nonrefundable in any circumstance.

STUDY DESIGN AND ETHICS

RESPONDING TO ALLEGATIONS OF POSSIBLE MISCONDUCT

The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation. As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.

When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper. In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.

Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.

If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record. If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.

All allegations will be kept confidential.

DEFINITIONS OF SCIENTIFIC MISCONDUCT

Mary Ann Liebert, Inc., publishers follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).

Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:

  • Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
  • Authorship Disputes: Deliberate misrepresentation of a scientist's contribution to the published work, or purposefully omitting the contributions of a scientist.
  • Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.
  • Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.
  • Material failure to comply with legislative and regulatory requirements affecting research: Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.
  • Conflict of Interest: Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
  • Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
  • Plagiarism: Purposely claiming another's work or idea as your own constitutes misconduct and/or fraud.
  • Simultaneous Submission: Submitting a paper to more than one publication at the same time constitutes misconduct.

RETRACTIONS

The journal and its publisher are committed to upholding the proper protocols and established standards of peer review.  Published papers found to be in violation of any of the misconduct noted above, or in the accepted principles of peer review and scientific publishing, will be officially retracted from the literature.  An official retraction notice explaining in full detail the circumstances surrounding the need for a retraction.

Three versions of the article format versions are referenced in the below policy guidelines:

1. Submitted Version: The submitted manuscript version is the version that is submitted by the author for consideration but has not yet been peer reviewed. This version may be posted anywhere, including preprint servers, with no embargo.

After acceptance, authors must include an acknowledgement of acceptance for publication on all archive sites and, following online publication, authors must include the following notice on the first page:  This is the original submission version (pre-peer review) of the following article: [full citation], which has now been formally published in final form in [journal title] at [link to final article using the DOI]. This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers’ self-archiving terms and conditions.

 

2.  Accepted Version: The manuscript version that has been formally accepted by the journal editor(s) after peer review in the journal but prior to any copyediting, typesetting, page proofs, or corrections. This version may be posted as follows:

  • Posted on authors’ personal site(s) with no embargo.
  • Posted on institutional repository with a 12-month post-publication embargo.
  • Posted on non-commercial subject-based repository, such as PubMed Central (PMC), with a 12-month post-publication embargo.

Authors also have the option to publish their papers as Gold Open Access (OA) under any of the Creative Commons Licenses available through the Publisher which would remove the embargos above. Please contact us for more information for open access options.

3.    Article of Record:  The final typeset, author-corrected, paginated version.   Authors are not permitted to publish or self-archive the Article of Record on any website, social media platform, or repository without permission from Mary Ann Liebert, Inc., publishers, unless they publish their paper Gold Open Access (OA) under any of the Creative Commons Licenses available through the Publisher. If you have questions, please contact us for more information. You can also review our Open Access policies and Licenses.

Funder Requirements
Mary Ann Liebert, Inc. publishers adheres to national and international funder requirements. Various funders, such as the National Institutes of Health (NIH), Wellcome Trust, Howard Hughes Medical Institute (HHMI), The Bill & Melinda Gates Foundation, and UK Research and Innovation (UKRI), for example, have specific requirements for depositing the accepted version and/or the article of record version of the author manuscript in a repository after an embargo period. Authors funded by these organizations should follow the self-archiving terms and conditions of these separate agreements based on the policies of the specific funding institutions. If you have questions, please contact us for more information.

Terms and Conditions for Use of All Self-Archived Article Versions
Authors may use either the original submission version or accepted version in the following ways:

  • For purposes of your own curriculum or teaching, dissertation, thesis, or book provided that all posted versions include the aforementioned policies, and follow all guidelines and requirements specified.
  • To share with researchers and research colleagues provided that such sharing is not for commercial purposes.

The self-archived submitted and accepted versions may only be used in non-commercial capacities. Individual users may view, print, download, and copy self-archived articles, as well as text and data mine the content conditions for non-commercial and non-promotional research and private study purposes, under the following requirements:

  • The authors' moral rights are not compromised and there is clear "attribution" of the author(s) in the shared work.
  • The authors’ integrity remains intact; the work should never be altered in such a way that the author's reputation may be damaged.
  • Any reuse complies with the copyright policies of the owner of that content.
  • Self-archived content may never be republished verbatim in whole or in part in print or online formats.

Please direct any questions regarding these policies to our Permissions Manager.

The Office of Foreign Assets Control (OFAC) of the US Department of the Treasury administers and enforces economic and trade sanctions based on US foreign policy and national security goals against targeted foreign countries and regimes, terrorists, international narcotics traffickers, those engaged in activities related to the proliferation of weapons of mass destruction, and other threats to the national security, foreign policy or economy of the United States. (Source: https://www.treasury.gov/about/organizational-structure/offices/pages/office-of-foreign-assets-control.aspx)

Our journal editors welcome contributions from researchers around the world; however, they are also required to follow sanction laws and regulations. Upon the date of this update (August 2020), sanction measures imposed by the United States, United Nations, European Union, and Australia are currently in place against the following countries: Cuba, Crimea, Iran, North Korea, and Syria. Journal editors will treat with caution any submission from a sanctioned country regarding the subject matter and will seek appropriate legal advice from the publisher if necessary.

Papers from sanctioned countries that are submitted to any Mary Ann Liebert, Inc., journal MUST contain a confirmation statement after the conclusion section of the manuscript which indicates that EACH listed author confirms that their research is supported by an institution that is primarily involved in education or research.

For further questions, please contact our Director of Production and Editorial Operations.

ARCHIVING AND PRESERVATION

Mary Ann Liebert, Inc., deposits and archives all publications in Portico for long-term digital preservation. Your article will be easily searchable on Google, Google Scholar, and other search engines.

PUBLISHER

Journal of Adolescent and Young Adult Oncology is owned and published by Mary Ann Liebert, Inc., publishers, 140 Huguenot Street, 3rd Floor, New Rochelle, NY 10801; Tel: 914-740-2100; Email: Info@liebertpub.com; Website: www.liebertpub.com/JAYAO

Mary Ann Liebert, Inc., publishers has partnered with Editage and Impact Science to provide a dynamic suite of specialized editorial services to ensure your manuscript has the impact it deserves.

 

Make Your Manuscript Submission-Ready

English Language Editing Services
Our pre-submission English Language Editing Services pair you with a highly qualified native English-speaking editor within your specific field of study. Dedicated support includes a detailed review of grammar, punctuation, terminology, and spelling, as well as an intensive edit for organization. We also offer post-submission support where needed.

English-Language Translation with Editing Services
Write your paper in your native language and our expert team will provide you with a translation that meets international publication standards while preserving the science and accuracy of your manuscript. Our translators and editors offer subject-specific expertise and editing skills to ensure that your manuscript conveys every nuance of your research to a global audience.

 

Accelerate Your Research Impact

Research Promotion Services
Amplify your research with engaging infographics, video abstracts, plain language summaries, and more to ensure your manuscript is discovered, read, and cited. Our specialized team of communication experts, scientists, and designers will transform your research into impactful text, graphical, and audio-visual formats that resonate with a wider audience and increase engagement.

Visit our Author Services portal now for more information and to get started!

 

All Editage services are fee-based services that authors can opt-into as an added author benefit to amplify the readability, visibility, findability, and shareability of their work.

Liebert Open Access

Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option

Explore Liebert Open Access

Does your research funder have an open access mandate or would you like to expand the dissemination of your research?

The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.

The benefits of Liebert Open Access include:

  • High visibility; open access articles are freely available online upon publication
  • You retain copyright with the open access license allowing broad dissemination of your research
  • You can freely share your article in repositories and research networks without restrictions
  • Easy compliance with open access mandates
  • Rigorous editorial and peer-review
  • Targeted email announcement featuring a direct link to article

Identification and Marketing

Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.

Copyright and Licensing

If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

At this time we allow authors to choose between the CC-BY or CC-BY-NonCommercial license. A limited number of journals offer NonCommercial licenses exclusively.

Ordering Open Access

Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email openaccess@liebertpub.com.

Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form.  You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.

Publishing biomedical or biotechnology research?

Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.

 *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.

 

Browse journals in the Liebert Open Access portfolio:

JOURNAL FEES

  • There are no submission fees to Journal of Adolescent and Young Adult Oncology.
  • There no page charges for Journal of Adolescent and Young Adult Oncology.
  • Please contact AuthorBenefits@liebertpub.com for costs for publishing images in color.
  • Open Access and Creative Commons licensing options are available. Contact our Open Access Manager for more information.
  • For pricing and purchasing reprints, contact our Reprints Manager.
  • Any fees collected or payments associated with a submitted and/or published paper that is subsequently withdrawn and/or retracted for any reason are non-refundable.
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.